Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

A Molecular Hinge Allows Transport Proteins to Move Neurotransmitters Across Brain Cell Membranes

By BiotechDaily International staff writers
Posted on 13 May 2013
Image: Senior author Dr. Shimon Schuldiner (Photo courtesy of the Hebrew University of Jerusalem).
Image: Senior author Dr. Shimon Schuldiner (Photo courtesy of the Hebrew University of Jerusalem).
An international team of molecular biologists has developed a model that shows how components of a protein transport complex act as a molecular hinge to move neurotransmitters across brain cell membranes.

Investigators at the Hebrew University of Jerusalem (Israel) and the Max Planck Institute of Biophysics (Frankfurt am Main, Germany) focused on vesicular monoamine transporter 2 (VMAT2), a member of the largest superfamily of transporters, which is known to convey a variety of neurotransmitters such as adrenaline, dopamine, and serotonin as well as MPP, a neurotoxin linked to Parkinson’s disease.

In the April 9, 2013, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) they described the importance of two anchor points positioned between two six-transmembrane-helix bundles. These two domains provide hinge points about which the two halves of the protein flex and straighten to open and close the translocation pathway, a process that enables alternating exposure of the substrate-binding site. Polar residues that create a hydrogen bond cluster form one of the anchor points of VMAT2, while the other results from hydrophobic interactions.

The investigators, led by Dr. Shimon Schuldiner, professor of biochemistry at the Hebrew University of Jerusalem, said that, "They hope that this knowledge may, in the future, help in designing drugs for treating pathologies involving transporters similar to VMAT, including infectious and neurological diseases."

Related Links:
Hebrew University of Jerusalem
Max Planck Institute of Biophysics



Channels

Business

view channel

License Agreement to Promote Development of Therapeutic CDK Inhibitors

A license agreement has been signed that was designed to promote the development and commercialization of a series of highly-selective cyclin-dependent kinase 7 (CDK7) inhibitors for the treatment of cancer, inflammation, and viral infections. Cyclin-dependent kinases (CDKs) play a pivotal role in cell cycle control... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.